BTK Inhibitors discussion - How do they work and what do patients prefer?

On behalf of the International Waldenstrom's Macroglobulinemia Foundation (IWMF), the Lymphoma Hub was pleased to speak with Stephen Ansell, Mayo Clinic, Rochester, US, who chaired a discussion on Bruton’s tyrosine kinase (BTK) inhibitors: How do they work and what do patients prefer? This discussion also featured Christian Buske, Monique Minnema, and Sheeba Koshy Thomas. The key discussion topics included:

• Mode of action of BTK inhibitors
• Important factors to consider when choosing BTK inhibitors as a frontline therapy, including age, genomic landscape, patient decisions, and side effects
• Expectations and durability of response of BTK inhibitors
• Side effects associated with BTK inhibitors
• Treatment options for patients progressing on BTK inhibitors
• Patient preferences